Skip to content

Author

Rosario García Campelo

We have 5 of 29 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD.

BACKGROUND ORCHARD (NCT03944772) was a biomarker-directed, phase II, platform study conducted to characterize resistance mechanisms and evaluate novel treatment combinations in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) following progression on first-line osimertini...

J. Goldman, J. W. Riess, Byoung Chul Cho et al. · 0 citations
Oct 2026

Systemic administration of poly(I:C) and resiquimod reprograms tumor-associated macrophages and prevents tumor progression and metastasis in murine cancer models.

It is demonstrated that intravenous administration of the poly(I:C)+R848 combination effectively reprograms TAMs, suppressing tumor progression and preventing metastasis across a variety of preclinical models of difficult-to-treat solid tumors.

Clément Anfray, A. Pensado-López, F. Castro et al. · 0 citations
Open access Feb 2025

A breast tissue-specific epigenetic clock provides accurate chronological age predictions and reveals de-correlation of age and DNA methylation in tumor-adjacent and tumor samples

Epigenetic clocks have been widely used to estimate biological age across various tissues, but their accuracy in breast tissue remains suboptimal. Pan-tissue models such as Horvath’s and Hannum’s clocks, perform poorly in predicting chronological age in breast tissue, underscoring the need for a tissue-specific approac...

L. Garma, S. Pernas, B. Fullana et al. · 1 citation
Clinical trial Sep 2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

This study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.

X. Le, A. Passaro, Yuan-Yuan Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.